Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals

Brüggemann, Roger J. M.; Moes, Dirk Jan A R; Rhee, Koen P. van; Veer, Nils E van 't; Koch, Birgit C. P.; Rossum, Mara van; Tweel, A. Vermeulen Windsant van Den; Reijers, Monique H.; Kimmenade, Roland R.J. van; Rahamat-Langedoen, Jannette; Rettig, Thijs C.D.; Raalte, Rutger van; Paassen, Judith van; Polderman, Florens; Linden, Paul D. van der; Frenzel, Tim; Mast, Quirijn de; Burger, David M.; Schouten, Jeroen; Veerdonk, Frank L. van de; Pickkers, Peter; Heine, Rob ter

doi:10.1016/j.ijantimicag.2021.106293

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many hospitals use hydroxychloroquine, lopinavir/ritonavir, and azithromycin, but their effectiveness and safety are still controversial [109]. It is also important to note that high doses of chloroquine may result in increased mortality and prolonged QT intervals in lifethreatening situations compared to low doses of chloroquine, suggesting that appropriate dose studies are needed before applying drugs to the treatment of COVID-19 [110]. A metaanalysis of 27 randomized controlled trials showed that compared with routine nursing, IL-6 antagonist significantly reduced the short-term mortality of COVID-19 patients, which was more obvious in patients receiving corticosteroids [111].…”

Section: Antiviral Therapymentioning

confidence: 99%

Effects of COVID-19 on Arrhythmia

Zhan

Yue

Liang

et al. 2022

JCDD

View full text Add to dashboard Cite

The World Health Organization announced that COVID-19, with SARS-CoV-2 as its pathogen, had become a pandemic on 11 March 2020. Today, the global epidemic situation is still serious. With the development of research, cardiovascular injury in patients with COVID-19, such as arrhythmia, myocardial injury, and heart failure, is the second major symptom in addition to respiratory symptoms, and cardiovascular injury is related to the prognosis and mortality of patients. The incidence of arrhythmia in COVID-19 patients ranges from 10% to 20%. The potential mechanisms include viral infection-induced angiotensin-converting enzyme 2 expression change, myocarditis, cytokine storm, cardiac injury, electrophysiological effects, hypoxemia, myocardial strain, electrolyte abnormalities, intravascular volume imbalance, drug toxicities and interactions, and stress response caused by virus infection. COVID-19 complicated with arrhythmia needs to be accounted for and integrated in management. This article reviews the incidence, potential mechanisms, and related management measures of arrhythmia in COVID-19 patients.

show abstract

Section: Antiviral Therapymentioning

confidence: 99%